Abstract
Recurrent mutually exclusive somatic mutations including BRAF, NRAS, and KIT are among the most common genetic aberrations underlying pathogenesis of melanoma. Testing for these mutations can be useful in providing diagnostic, therapeutic, and prognostic information. Molecular diagnostic techniques for mutational analysis are becoming standard of care in melanoma as the detection of these mutations will contribute to the development of molecular classification of melanocytic tumors and guides through choosing the most appropriate therapy in the era of personalized medicine.